Apellis Reports Top-Line Results from Phase III Studies Evaluating Pegcetacoplan for Geographic Atrophy

Apellis Pharmaceuticals has announced the top-line results from two Phase III studies, evaluating intravitreal pegcetacoplan as a treatment for geographic atrophy.